Cargando…
Recent advances in transthyretin amyloidosis therapy
Mutant (MT) forms of transthyretin (TTR) cause the most common type of autosomal-dominant hereditary systemic amyloidosis—familial amyloidotic polyneuropathy (FAP). Until 20 years ago, FAP was thought to be an endemic disease, but FAP is known to occur worldwide. To date, more than 130 mutations in...
Autores principales: | Ueda, Mitsuharu, Ando, Yukio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165622/ https://www.ncbi.nlm.nih.gov/pubmed/25228988 http://dx.doi.org/10.1186/2047-9158-3-19 |
Ejemplares similares
-
Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2022) -
Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal
por: Ando, Yukio, et al.
Publicado: (2023) -
Evolving landscape in the management of transthyretin amyloidosis
por: Hawkins, Philip N., et al.
Publicado: (2015) -
New simple and quick method to analyze serum variant transthyretins: direct MALDI method for the screening of hereditary transthyretin amyloidosis
por: Nomura, Toshiya, et al.
Publicado: (2019) -
Recent Advances and Current Dilemmas in the Diagnosis and Management of Transthyretin Cardiac Amyloidosis
por: Addison, Daniel, et al.
Publicado: (2021)